Virtual Forum: Introducing RASP: Relapse Assessment In Schizophrenia Patients
Location: Online Via PsychU.org
Description: Nearly 3.4 million adults, or 1.1% of the U.S. population, have a diagnosis of schizophrenia.1,2 As a chronic, relapsing3 condition, those who have schizophrenia may experience worsening of symptoms, repeat hospital stays,4,5 and a decrease in medication efficacy6 – which may contribute to costly care. Additionally, past relapses may predict an increased risk of future relapses and higher annual mental health care costs.7,8
Join Heidi Waters, MBA, PhD, Director of Outcomes Management with Otuska Pharmaceutical Development & Commercialization, Inc., as she presents a new self-report screening tool to assess for relapse risk in patients with schizophrenia. The Virtual Forum will touch on what schizophrenia is, what the annual cost burden is in the U.S., and how relapse factors in. In addition, it will also discuss the new, validated, and reliable questionnaire, RASP.9
Speaker is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc.
1. Regier, D.A., et. al. (1993). The de facto us mental and addictive disorders service system: Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Archives of General Psychiatry, 50(2): 85-94. 2. United States Census Bureau. (2011). Age and sex composition: 2010. 2010 Census Briefs. Hagerstown, MD: U.S. Department of Commerce Economics & Statistics Administration, U.S. Census Bureau. 3. American Psychiatric Association (APA). (2013). Schizophrenia and other psychotic disorders. Diagnostic & Statistical Manual Of Mental Disorders Fifth Edition (DSM-5), 87-122. Arlington, VA / Washington, DC: APA. 4. Schennach, R., et. al. (2012). Predictors of relapse in the year after hospital discharge among patients with schizophrenia. Psychiatric Services, 65(1), 87-90. 5. Lieberman, J.A., et. al. (2001). The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biological Psychiatry, 50, 884-897. 6. Leiberman, J.A., et. al. (1996). Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology, 14(35), 144-215. 7. Ascher-Svanum, H., et. al. (2010). The cost of relapse and the predictors of relapse in the treatment of schizophrenia. [Additional File 3: Table S3. Logistic regression analyses of relapse predictors for the 1557 participants and by relapse status.] BMC Psychiatry, 10(2). 8. Ascher-Svanum, H., et. al. (2010). The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry, 10(2). 9. Velligan, D., et. al. (2018). Relapse risk assessment for schizophrenia patients (RASP): A new self-report screening tool. Clinical Schizophrenia & Related Psychoses, Winter 2018, 224-235.